Wang Qinbo, Zhou Yuan, Li Hua, Ou Yingjuan, Fei Jiaxi, Wu Xia, Chen Junrong, Li Xiaoyan
Department of Pharmacy, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
Department of Graceland Medical Center, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
Front Oncol. 2025 Jul 17;15:1595010. doi: 10.3389/fonc.2025.1595010. eCollection 2025.
To explore a practical complications related Medication Therapy Management (MTM) service for colorectal cancer patient which based on take home cancer drugs (THCDs), and minimize the occurrence of unexpected events by reducing complications and adverse reactions in home therapy.
A total of 144 patients with colorectal cancer (CRC) who underwent home cancer drugs treatment for the first time met the include criteria from July 1, 2023 to July 31, 2024. They were divided into control group and MTM intervention group randomly, MTM intervention group conducted with three courses of MTM intervention, and control group adapt with three times of conventional follow up. We compared patient characteristics, complications, adverse effects, and knowledge-practice-attitude (KPA) results.
Among them, 119 patients were enrolled. There were significant differences regard of cancer pain, insomnia, anxiety, and defecation disorder (p<0.05); Multivariate analysis results showed that pain, chemotherapy-induced nausea or vomiting (CINV), and defecation disorder were independent factors for unscheduled hospital admission (p<0.05); There were significant differences regard of adverse effects for home medication patient which include jaundice, hypo leukocytosis, limb edema, and fatigue (p<0.05); MTM intervention group showed better feedback than control group in Attitudes and practice Toward screening (p<0.05).
MTM demonstrates significant clinical benefits in colorectal cancer (CRC) patients by effectively reducing the incidence of treatment-related complications, including nausea and vomiting (CINV), abdominal pain, and insomnia. Furthermore, it contributes to decreased rates of unplanned hospitalization and enhances key patient outcomes (KPA), warranting further investigation and clinical application in CRC management.
探索一种基于居家抗癌药物（THCDs）的针对结直肠癌患者的实用药物治疗管理（MTM）服务并发症，并通过减少居家治疗中的并发症和不良反应来尽量减少意外事件的发生。
2023年7月1日至2024年7月31日，共有144例首次接受居家抗癌药物治疗的结直肠癌（CRC）患者符合纳入标准。他们被随机分为对照组和MTM干预组，MTM干预组进行三个疗程的MTM干预，对照组进行三次常规随访。我们比较了患者特征、并发症、不良反应以及知识-实践-态度（KPA）结果。
其中，119例患者被纳入研究。在癌症疼痛、失眠、焦虑和排便障碍方面存在显著差异（p<0.05）；多因素分析结果显示，疼痛、化疗引起的恶心或呕吐（CINV）和排便障碍是计划外住院的独立因素（p<0.05）；居家用药患者的不良反应，包括黄疸、白细胞减少、肢体水肿和疲劳方面存在显著差异（p<0.05）；MTM干预组在对筛查的态度和实践方面比对照组有更好的反馈（p<0.05）。
MTM通过有效降低与治疗相关的并发症（包括恶心和呕吐（CINV）、腹痛和失眠）的发生率，在结直肠癌（CRC）患者中显示出显著的临床益处。此外，它有助于降低计划外住院率并改善关键患者结局（KPA），值得在CRC管理中进一步研究和临床应用。
